Latest News and Press Releases

Third quarter 2018 revenue increased 25% to $3.2 million, compared with $2.5 million in same period in 2017  Third quarter 2018 gross profit increased 60% compared to same period in 2017 ...

MODI’IN, Israel and MANASQUAN, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...

Second quarter 2018 revenue increased 53% to $3.4 million, compared with $2.2 million in same period in 2017The Company estimates total revenues for 2018 to reach $13 -14 million, an increase of 37 –...

Studies will use BreathID 13C-methacetin breath test to evaluate patient response to therapy MODI’IN, Israel and MANASQUAN, N.J., July 10, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd....

MODI’IN, Israel and MANASQUAN, N.J., June 18, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...

Healthcare Industry Veteran Brings Track Record of Success    MODI’IN, Israel and MANASQUAN, N.J., April 30, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and...

MODI'IN, Israel and MANASQUAN, N.J., March 13, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...

- 2017 revenue increased 127% to $9.5 million, compared with $4.2 million in 2016 -  - Fourth quarter 2017 revenue increased 161% compared with same period in 2016 - MODI’IN, Israel and MANASQUAN,...

MODI’IN, Israel and MANASQUAN, N.J., March 09, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...

Easy-to-administer, noninvasive BreathID® test offers multiple advantages over alternative invasive detection methods Potential 2020 entry to an addressable U.S. market of millions of NASH patients ...